← FDA DRUG APPROVALS

FDA ANDA · ANDA206986

HYDROCODONE BITARTRATE

Sponsor: ALVOGEN

APPLICATION
ANDA206986
TYPE
ANDA
ORIGINAL APPROVAL
2020-01-21
LATEST ACTION
2026-06-18
ROUTE
ORAL
DOSAGE FORM
CAPSULE, EXTENDED RELEASE
MARKETING STATUS
Prescription

Products

HYDROCODONE BITARTRATEPrescription
HYDROCODONE BITARTRATE 50MG · CAPSULE, EXTENDED RELEASE · ORAL
HYDROCODONE BITARTRATEPrescription
HYDROCODONE BITARTRATE 30MG · CAPSULE, EXTENDED RELEASE · ORAL
HYDROCODONE BITARTRATEPrescription
HYDROCODONE BITARTRATE 15MG · CAPSULE, EXTENDED RELEASE · ORAL
HYDROCODONE BITARTRATEPrescription
HYDROCODONE BITARTRATE 40MG · CAPSULE, EXTENDED RELEASE · ORAL
HYDROCODONE BITARTRATEPrescription
HYDROCODONE BITARTRATE 20MG · CAPSULE, EXTENDED RELEASE · ORAL
HYDROCODONE BITARTRATEPrescription
HYDROCODONE BITARTRATE 10MG · CAPSULE, EXTENDED RELEASE · ORAL

Approval history

2026-06-18REMS · Supplement 10AP
2025-12-22Labeling · Supplement 8 · standardAP
2025-09-26Labeling · Supplement 6 · standardAP
2024-10-31REMS · Supplement 7AP
2023-12-15Labeling · Supplement 5 · standardAP
2023-12-11Labeling · Supplement 3 · standardAP
2020-01-21UNKNOWN · Original · standardLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →